Acutus Medical launches AcQMap cardiac mapping tech in US

Acutus Medical said today it launched the AcQMap high-resolution imaging & mapping system and the 3D mapping catheter that goes by the same name, touting that the system had been used in its first commercial procedures.

The Carlsbad, Calif.-based company said that AcQMap system is designed to detect and display standard voltage-based and higher resolution charge-source maps, and is able to generate real-time, 3D images of the heart chamber using ultrasound.

“Enabling physicians to see complex, irregular arrhythmias in real-time should provide important new insights and enable truly personalized and individualized ablation therapy planning.  We hope that this unique capability, combined with the ability to quickly re-map after each ablation, will lead the way to further improvements in clinical outcomes for patients suffering from complex arrhythmias. Together with institutions across the country, we hope to transform the lives of people suffering from complex arrhythmias through our innovative technology and are pleased that U.S. patients now have access to AcQMap,” prez & CEO Vince Burgess said in a press release.

Acutus Medical said that it has also launched a clinical study of the device exploring its use during atrial fibrillation retreatment ablation procedures.

Last October, Acutus Medical said that it won 510(k) clearance from the FDA for its AcQMap system. The system won CE Mark approval in the European Union in May 2016.

The post Acutus Medical launches AcQMap cardiac mapping tech in US appeared first on MassDevice.

Medtronic taps former JP Morgan analyst Weinstein for strategy SVP | Personnel Moves – May 7, 2018

Medtronic (NYSE:MDT) said today it tapped former J.P. Morgan Chase & Co. analyst Mike Weinstein as its strategy senior VP.

Prior to joining Medtronic, Weinstein served as a managing director for JP Morgan’s equity research healthcare team, holding positions within the unit for more than 20 years, the Fridley, Minn.-based company said.

“We are excited to welcome Mike to Medtronic. He is deeply respected within the industry and brings with him vast knowledge of our markets, technologies, and growth strategies. I look forward to his contributions to the company, including his expert guidance and insights, as well as the new perspective he will bring to our organization,” Medtronic CEO Omar Ishrak said in a press release.

“Mike brings unique and deep insights of the medical device and technology space to Medtronic, developed during a distinguished career in equity research at J.P. Morgan. He will serve as an integral advisor and partner to our senior leaders, and we are thrilled to welcome him to the team,” Medtronic CFO Karen Parkhill said in a prepared statement.

Weinstein joined JP Morgan in 1992, and moved to become the senior medical technology analyst in 1996, Medtronic said. He will assume his position at Medtronic immediately.

“I see in Medtronic the opportunity to continue to create significant shareholder value, and I couldn’t be more excited to join the global leader in medical technology and contribute to its Mission. Having covered Medtronic for more than two decades now, I have full confidence in the outlook and the strategy, and our ability to unlock that value in the months and years ahead,” Weinstein said in a prepared release.

 Endologix lifts COO Onopchenko to the corner office

Endologix (NSDQ:ELGX) said last Wednesday it lifted former COO John Onopchenko to the role of chief executive officer, effective immediately.

Onopchenko served as COO since last October, the Irvine, Calif.-based company said. Prior to joining Endologix, Onopchenko acted as exec VP for Acutus Medical, and has held positions including COO at Volcano.

Onopchenko also spent 10 years at Johnson & Johnson (NYSE:JNJ) leading medical device investments with J&J’s Development Corporation, and held positions with General Electric (NYSE:GE) Medical, Endologix said.

“We are very pleased to welcome John as our chief executive officer. Over the course of the past seven months in the COO role, John has shown the board first hand that he is an exceptional operator with significant manufacturing, clinical, and regulatory experience. His proven skills in scaling and improving productivity in global commercial organizations at Johnson & Johnson and GE Medical and as a medical device venture capitalist give us confidence in his ability to lead Endologix on an exciting path forward. Separately, on behalf of the board of directors, I would like to thank John McDermott for his invaluable contributions to Endologix and for making this transition as smooth as possible,” board chair Dan Lemaitre said in a prepared statement.

“I am honored to be named chief executive officer of Endologix. Since joining the company as COO, I have been deeply involved in the operations of the organization, and I’m excited about the bright future that Endologix has ahead of it. I am looking forward to further advancing the company’s innovative portfolio, enhancing its credibility and reputation with our physicians and customers, and building a culture of accountability, with the ultimate goal of delivering value to our stakeholders around the globe,” Onopchenko said in a press release.

Read more

 Henry Schein names Connett as US medical head

Henry Schein (NSDQ:HSIC) said last week it appointed Brad Connett as its new US Medical Group president, lifting them from their previous position as US Medical commercial group prez.

“Brad has distinguished himself throughout his entire career, and he has been one of the architects of the remarkable growth that Henry Schein Medical has enjoyed in recent years. Brad’s new appointment reflects his excellence as a senior leader and his ability to drive continued growth,” board chair & CEO Stanley Bergman said in a press release.

Connett joined Henry Schein in 1997 after the company acquired Roane-Barker, the company said.

“Throughout the years, Henry Schein Medical has partnered with health care organizations to drive the development and execution of non-acute supply chain strategies. Brad’s strategic vision, deep-rooted industry knowledge, and wide network will advance our ability to deliver innovative solutions that helps our medical professionals operate efficient and profitable practices,” CCO David McKinley said in a prepared statement.

Read more

 Patterson Dental NA prez Misiak steps away

Patterson Dental (NSDQ:PDCO) said last week its North America president is leaving his role on May 11 to pursue a new opportunity.

The company said it will engage in a search for a new dental segment leader, and during the transition the dental biz will report to Mark Walchirk.

“We are grateful to Dave for his many contributions to Patterson during his 22 years with our dental business, and I thank him for his support during my transition. On behalf of Patterson, we wish him the best in his future endeavors,” prez & CEO Mark Walchirk said in a prepared release.

Read more

 Ex-Alere CFO Hinrichs leaves the healthcare field

Former Alere (NYSE:ALR) exec VP and CFO Jim Hinrichs has exited the healthcare industry, taking a position as CFO of plant breeding and production company Cibus.

During his time at Alere, Hinrichs initiated a performance improvement program looking to save over $150 million through integration, standardization and scale-building projects, according to a Cibus release. He also held a CFO position with CareFusion, Cibus said.

“Jim’s leadership will take Cibus to the next level as we execute sales for our robust pipeline of food and agricultural products. His impressive experience in the healthcare and biotech industries offers a well-rounded perspective and will bolster Cibus’ expanding presence in the agriculture industry,” Cibus prez & CEO Peter Beetham said in a press release.

Read more

The post Medtronic taps former JP Morgan analyst Weinstein for strategy SVP | Personnel Moves – May 7, 2018 appeared first on MassDevice.